reports
UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Result...
UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates - Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful improvement in BCVA and CST with favorable safety profile at 12 and 18 weeks - - Near-Term Milestones include 24-week Data in BEHOLD and 16-week Data in Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration by Year-End - - Tie2/VEGF Bispecific Program Achieved Advanced Candidat...
Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial R...
Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial Results; Updates Fiscal Year 2022 Revenue Guidance TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2022. Second Quarter 2022 Summary & Operating Highlights: Total revenue of $27.3 million, up $1.4 million, or 6%, year-over-year. U.S. revenue up 7% year-over-year.Total subscription and system revenue up 9% year-over-year. GAAP net lo...
- Adam Antoniak
Poland: July inflation sets new 2022 record
July CPI has been revised to 15.6% year-on-year, the highest level so far in 2022. Yet the inflation peak is still ahead of us and we expect it in the autumn as the heating season begins and drives up prices. The Monetary Policy Council (MPC) will be forced to hike rates further
Form 8.3 - Emis Group Plc
Form 8.3 - Emis Group Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:...
Rapid Micro Biosystems Announces Review of Strategic Alternatives to M...
Rapid Micro Biosystems Announces Review of Strategic Alternatives to Maximize Shareholder Value Rejects Unsolicited, Non-Binding Proposal from Kennedy Lewis Investment Management Adopts Limited Duration Stockholder Rights Plan LOWELL, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Board of Directors has initiated a review of st...
Rapid Micro Biosystems Provides Business Update and Reports Second Qua...
Rapid Micro Biosystems Provides Business Update and Reports Second Quarter 2022 Financial Results Reports second quarter 2022 commercial revenue of $3.9 million Lowers full year 2022 commercial revenue guidance to at least $17.0 million Implements organizational restructuring plan to right-size cost structure with focus on enhancing commercial execution and key product development programs to drive revenue growth CEO Robert Spignesi to assume commercial leadership responsibilities Announces review of strategic alternatives and rejection of Kennedy Lewis Management Proposal LOWELL, Mas...
Inseego MiFi® X PRO 5G UW hotspot now available at Verizon
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: INSG), a leader in 5G and intelligent IoT device-to-cloud solutions, today introduced the new MiFi® X PRO 5G UW mobile hotspot, delivering the full range of 5G connectivity including C-Band, along with Wi-Fi 6 for performance that packs more power and flexibility into one of the market’s most trusted mobile hotspots for business — all while retaining its all-day battery life1. The new MiFi® X PRO 5G UW is Verizon’s third generation 5G mobile hotspot by Inseego and now available to order in stores and . This press release features multimedia. View the full...
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
Iterum Therapeutics Reports Second Quarter 2022 Financial Results --Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2022. “We are excited to start ou...
Gencor Releases Third Quarter Fiscal 2022 Results
Gencor Releases Third Quarter Fiscal 2022 Results ORLANDO, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenues of $29.6 million for the quarter ended June 30, 2022 compared to $24.9 million for the quarter ended June 30, 2021. Gross margins for the quarter ended June 30, 2022 were 19.2% compared with 22.5% for the quarter ended June 30, 2021. Higher manufacturing costs associated with wages, steel, and purchased parts continued to impact the Company’s operating results for the quarter ended June 30,...
Applied Therapeutics Reports Second Quarter 2022 Financial Results
Applied Therapeutics Reports Second Quarter 2022 Financial Results Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2H 2022, including Galactosemia 12 month data analysis, SORD Deficiency biomarker data, and DbCM full enrollment NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Co...
Humacyte Second Quarter 2022 Financial Results and Business Update
Humacyte Second Quarter 2022 Financial Results and Business Update -- Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – -- Hosted key opinion leader (KOL) webinar on HAV in the treatment of vascular trauma, featuring Ernest E. Moore, M.D and Gregory A. Magee, M.D. – -- Strengthened Board of Directors with appointment of Diane Seimetz, Ph.D. and leadership team with appointment of Shamik Parikh, M.D. as Chief Medical Officer – -- Multiple scientific meeting presentations and publications highlighting clini...
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent...
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. “We have achieved several milestones in the first half of 2022, and some import...
Ocean Power Technologies to Report 2023 First Quarter Results on Monda...
Ocean Power Technologies to Report 2023 First Quarter Results on Monday, September 12, 2022 MONROE TOWNSHIP, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it will report its fiscal 2023 first quarter after the market closes on Monday, September 12, 2022. CONFERENCE CALL AND WEBCAST INFORMATION A conference call to discuss the financial results will be held the following morning Tuesday, September 13,...
Silver Spike Investment Corp. Reports First Quarter Fiscal 2023 Financ...
Silver Spike Investment Corp. Reports First Quarter Fiscal 2023 Financial Results NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Silver Spike Investment Corp. (“Silver Spike” or the “Company”), a specialty finance company that was formed to invest across the cannabis ecosystem through investments in the form of direct loans to, and equity ownership of, privately held cannabis companies, today announced its financial results for the quarter ended June 30, 2022. First Quarter 2023 Highlights1 Total investment income of $0.8 millionNet investment income of $0.2 million, or $0.04 per shareFund...
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81...
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg Results of National Patient Experience Survey Show 95% Satisfaction Rate with VAZALORE 81 mg as Aspirin Therapy Choice FDA-Approved VAZALORE Delivers Fast, Reliable Absorption of Aspirin SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the mark...
The Real Good Food Company Reports Second Quarter 2022 Financial Resul...
The Real Good Food Company Reports Second Quarter 2022 Financial Results and Raises 2022 Net Sales Outlook CHERRY HILL, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- The Real Good Food Company, Inc. (Nasdaq: RGF) (“Real Good Foods” or the “Company”), an innovative, high-growth, branded, health- and wellness-focused frozen food company, today reported financial results for its second quarter ended June 30, 2022. “I am pleased with our solid second quarter revenue growth driven by both new and existing customers,” said Bryan Freeman, Executive Chairman. “We have seen strong growth in retail groc...
Ocuphire Pharma Announces Financial Results for the Second Quarter 202...
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval Positive Results from Phase 3 LYNX-1 Trial of Nyxol in Night Vision Disturbances (NVD) Mark Sixth Positive Nyxol Clinical Data Readout Across Multiple Indications Data Expected in 2H 2022 from Phase 2b Trial of APX3330, a Potential First-in-Class Oral Treatment for Diabetic Retinopathy Plans to In...
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of...
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment UBX1325 treatment also stabilized retinal structure, as measured by central subfield thickness (CST) at 12- and 18-weeks, as compared to worsening in sham-treated patients The treatment effect was seen in a patient population with visual acuity deficits and residual ...
Soluna Holdings, Inc. to Present at Investor Summit Group's Q3 Virtual...
Albany, New York--(Newsfile Corp. - August 12, 2022) - Soluna Holdings, Inc. (NASDAQ: SLNH) today announced that Michael Toporek, CEO of Soluna Holdings will be attending the Q3 Virtual Investor Summit. Soluna Holdings, Inc. is the leading developer of green, modular, scalable data centers for computing-intensive, batchable applications such as cryptocurrency mining, AI, and machine learning, powered by wasted renewable energy. Event: Q3 Investor Summit Date: August 16 & 17th, 2022 Presentation: August 16 @ 2:45 p.m. ET Location: 1x1s will be available for qualified investorsThe conference...
Budweiser Celebrates 100 Days to The FIFA World Cup™ by Partnering wit...
LEUVEN, Belgium--(BUSINESS WIRE)-- Tomorrow, Budweiser, an Anheuser-Busch InBev (AB InBev) global brand will “drop” prizes in select destinations in the lead up to the biggest global sporting event. As the Official Beer of the FIFA World Cup, Budweiser is giving fans the once-in-a-lifetime chance to experience the FIFA World Cup in person by dropping hundreds of red prize boxes in major cities that include signed memorabilia, a year’s supply of Budweiser, and the grand prize of a trip to the tournament. This press release features multimedia. View the full release here: Budweiser's QR code (Gr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.